The two new PhD students were selected after an extensive international recruitment process where nearly 200 applicants at MSc level competed for the two positions.
The two graduate students will pursue their doctoral studies at the Karolinska Institutet (KI) and carry out their research at both Kancera and KI.
One PhD student, Anna Huguet Ninou (MSc in Drug Discovery), will study the biology of the Kancera target molecule PFKFB3 and its role in DNA repair. This work will be done in close collaboration with Thomas Helleday’s group at KI. Anna has a BSc from the Universitat Autònoma de Barcelona and worked at the Vrije Universiteit Amsterdam, where she received her MSc in Drug Discovery.
The second PhD student, Jemina Lehto (MSc in Physiology and Genetics), will study a new hypothesis regarding the link between fractalkine signaling and DNA repair. Jemina will also work in close collaboration with researchers at KI. Jemina completed her MSc at the University of Turku. She has also carried out exchange studies at Ghent University in Belgium, and the Experimental Therapeutics Center, A*STAR in Singapore.
"We are very pleased to have been able to recruit these highly qualified young scientists and look forward to exciting research results from the SYNTRAIN program. We welcome Anna and Jemina to Kancera "said Martin Norin, COO of Kancera.
SYNTRAIN (The European synthetic lethality training network) aims to identify new molecules for future, innovative breast and ovarian cancer treatments.
SYNTRAIN is comprised of the world's leading scientists with complementary expertise in genetic stability and DNA damage processes. The consortium has gathered a critical mass of expertise to provide an excellent education in screening methods, mechanistic studies and drug development.
SYNTRAIN is a new European Training Network (ETN), funded by the European Commission under the program Horizon in 2020.
Learn more about SYNTRAIN on: http://syntrain.ku.dk/
About Kancera AB (publ)
Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of leukemia and solid tumors, based on blocking survival signals in the cancer cell and on addressing cancer metabolism. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 15 people. Kancera shares are traded on NASDAQ First North and the number of shareholders were more than 7700 as of January 13th, 2017. FNCA is Kancera’s Certified Adviser. Professor Carl-Henrik Heldin, Professor Håkan Mellstedt, and MD PhD Charlotte Edenius are board members and Kancera´s scientific advisers.
For further information contact,
Thomas Olin, CEO: +46-735-20 40 01
Kancera AB (publ)
Karolinska Institutet Science Park
SE 171 48 Solna
Visit our home page at: https://www.kancera.com.